ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
The safety profile of lenalidomide, dexamethasone, daratumumab, and bortezomib combinations in multiple myeloma: a retrospective analysis of the FAERS database.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The current study aimed to compare the real-world safety profiles of first-line multiple myeloma regimens-lenalidomide plus dexamethasone (Rd), bortezomib plus lenalidomide and dexamethasone (VRd), and daratumumab plus lenalidomide and dexamethasone (DRd)-using the FDA Adverse Event Reporting System (FAERS) database. A large-scale retrospective analysis was conducted on 54,243 cases from the FAERS database (2004-2025). Analytical methods included trend analysis, disproportionality analysis (using Bayesian Information Component and Reporting Odds Ratio), co-medication assessment for drug-drug interactions, and time-to-onset analysis with Weibull modeling. Trend analysis reveals a steady increase in DRd adoption since its introduction in 2016, contrasting with a decline in Rd reports after 2021 and a modest decrease in VRd cases after 2020, potentially reflecting the emergence of new therapeutic alternatives and growing safety concerns. Disproportionality analyses confirm significantly elevated signals for infections associated with DRd and neurological disorders linked to VRd across multiple subgroup analyses. Co-medication assessments suggested potential drug-drug interaction signals associated with increased reporting frequencies of these adverse events. Time-to-onset analysis indicates an earlier manifestation of infectious complications with DRd. The findings support the potential value of regimen-specific safety monitoring: proactive infection prophylaxis for DRd recipients and subcutaneous bortezomib with neurological surveillance for VRd patients. This real-world evidence complements clinical trials and guides personalized treatment strategies to optimize the risk-benefit balance in multiple myeloma management.
Indexed as
Identifiers
42171749What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.